Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) Jg. 147; H. 25; S. 1891
Hauptverfasser:	Piazza, Gregory, Spyropoulos, Alex C, Hsia, Judith, Goldin, Mark, Towner, William J, Go, Alan S, Bull, Todd M, Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S, Bonaca, Marc P
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 20.06.2023
Schlagworte:	Anticoagulants - adverse effects COVID-19 Hemorrhage - chemically induced Hemorrhage - drug therapy Hospitalization Humans Outpatients Rivaroxaban - adverse effects Thrombosis - epidemiology Thrombosis - prevention & control COVID-19 pre-exposure prophylaxis prevention and control rivaroxaban thrombosis venous thromboembolism
ISSN:	1524-4539, 1524-4539
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!